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Abstract
Although strong epidemiologic evidence suggests an important
role for adaptive immunity in the pathogenesis of polyarticular
juvenile rheumatoid arthritis (JRA), there remain many aspects of
the disease that suggest equally important contributions of the
innate immune system. We used gene expression arrays and
computer modeling to examine the function in neutrophils of 25
children with polyarticular JRA. Computer analysis identified
712 genes that were differentially expressed between patients
and healthy controls. Computer-assisted analysis of the
differentially expressed genes demonstrated functional
connections linked to both interleukin (IL)-8- and interferon-γ
(IFN-γ)-regulated processes. Of special note is that the gene
expression fingerprint of children with active JRA remained
essentially unchanged even after they had responded to
therapy. This result differed markedly from our previously
reported work, in which gene expression profiles in buffy coats
of children with polyarticular JRA reverted to normal after
disease control was achieved pharmacologically. These findings
suggest that JRA neutrophils remain in an activated state even
during disease quiescence. Computer modeling of array data
further demonstrated disruption of gene regulatory networks in
clusters of genes modulated by IFN-γ and IL-8. These cytokines
have previously been shown to independently regulate the
frequency (IFN-γ) and amplitude (IL-8) of the oscillations of key
metabolites in neutrophils, including nicotinamide adenine
dinucleotide (phosphate) (NAD(P)H) and superoxide ion. Using
real-time, high-speed, single-cell photoimaging, we observed
that 6/6 JRA patients displayed a characteristic defect in 12%
to 23% of the neutrophils tested. Reagents known to induce
only frequency fluctuations of NAD(P)H and superoxide ion
induced both frequency and amplitude fluctuations in JRA
neutrophils. This is a novel finding that was observed in children
with both active (n  = 4) and inactive (n  = 2) JRA. A
subpopulation of polyarticular JRA neutrophils are in a chronic,
activated state, a state that persists when the disease is well
controlled pharmacologically. Furthermore, polyarticular JRA
neutrophils exhibit an intrinsic defect in the regulation of
metabolic oscillations and superoxide ion production. Our data
are consistent with the hypothesis that neutrophils play an
essential role in the pathogenesis of polyarticular JRA.
Introduction
The term juvenile rheumatoid arthritis (JRA) identifies a heter-
ogeneous family of disorders that share the common feature of
chronic inflammation and hyperplasia of the synovial mem-
branes. The pathogenesis of JRA is unknown. The histopathol-
ogies of adult and juvenile forms of rheumatoid arthritis are
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Table 1
Genes over-expressed in JRA neutrophils
GenBank accession no. Symbol Description Avg. control Avg. patients Ratio P/C
NM_001124 ADM Adrenomedullin 0.3 3.2 10.3
NM_001706 BCL6 B-cell CLL/lymphoma 6 (zinc finger protein 51) 54.0 179.9 3.3
NM_001729 BTC Betacellulin 0.2 2.8 12.1
NM_001295 CCR1 Chemokine (C-C motif) receptor 1 1.5 5.6 3.7
NM_001785 CDA Cytidine deaminase 10.9 30.6 2.8
NM_004360 CDH1 Cadherin 1, type 1, E-cadherin (epithelial) 0.3 2.2 6.4
NM_005194 CEBPB CCAAT/enhancer binding protein (C/EBP), beta 1.1 3.7 3.2
NM_000651 CR1 Complement component (3b/4b) receptor 1, including 
Knops blood group system
6.6 21.3 3.2
AF172398 F11R F11 receptor, JAM1 0.5 3.5 7.2
NM_002005 FES Feline sarcoma oncogene 35.6 108.3 3.0
NM_001462 FPRL1 Formyl peptide receptor-like 1 21.0 72.0 3.4
NM_000637 GSR Glutathione reductase 3.7 18.5 5.0
NM_015401 HDAC7A Histone deacetylase 7A 3.3 9.7 2.9
NM_002127 HLA-G HLA-G histocompatibility antigen, class I, G 336.2 956.2 2.8
NM_005345 HSPA1A Heat shock 70-kDa protein 1A 20.6 53.7 2.6
NM_014339 IL17R Interleukin 17 receptor 10.2 28.5 2.8
NM_000634 IL8RA Interleukin 8 receptor, alpha 13.6 53.9 4.0
BC017197 MCL1 Myeloid cell leukemia sequence 1 (BCL2-related) 5.3 21.5 4.1
NM_007289 MME Membrane metallo-endopeptidase (neutral 
endopeptidase, enkephalinase, CALLA, CD10)
9.5 29.5 3.1
NM_013416 NCF4 Neutrophil cytosolic factor 4 (40 kDa) 20.0 58.6 2.9
AF171938 NUMB Numb homolog (Drosophila) 3.2 11.6 3.7
NM_023914 P2RY13 purinergic receptor P2Y, G-protein coupled, 13, GPR86 8.7 32.0 3.7
NM_014143 PDCD1LG1 programmed cell death 1 ligand, B7-H1 0.3 5.1 15.3
NM_000442 PECAM1 Platelet/endothelial cell adhesion molecule (CD31 
antigen)
6.2 12.5 2.0
NM_001198 PRDM1 PR domain containing 1, with ZNF domain 0.8 6.8 8.9
NM_000962 PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/
H synthase and cyclooxygenase)
0.3 8.6 29.5
NM_002838 PTPRC Protein tyrosine phosphatase, receptor type, C 55.9 159.7 2.9
NM_002881 RALB V-ral simian leukemia viral oncogene homolog B (ras 
related-GTP binding protein)
5.2 15.8 3.0
NM_004761 RGL2 ral guanine nucleotide dissociation stimulator-like 2, RAB2 3.0 8.9 3.0
NM_005621 S100A12 S100 calcium binding protein A12 (calgranulin C) 62.9 164.0 2.6
NM_002964 S100A8 S100 calcium binding protein A8 (calgranulin A) 791.4 2,017.6 2.5
NM_002965 S100A9 S100 calcium binding protein A9 (calgranulin B) 1,152.7 2,697.1 2.3
D83782 SCAP SREBP CLEAVAGE-ACTIVATING PROTEIN 0.3 2.6 7.5
NM_022464 SIL1 Endoplasmic reticulum chaperone SIL1, homolog of yeast 0.3 5.0 14.9
NM_004171 SLC1A2 Solute carrier family 1 (glial high affinity glutamate 
transporter), member 2
7.5 32.9 4.4Available online http://arthritis-research.com/content/8/5/R154
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identical, suggesting common pathogenic mechanisms. Cur-
rent theories of disease pathogenesis originate from two key
observations: (a) the presence of CD4+ T lymphocytes dem-
onstrating a CD45RO+ ('memory') phenotype in inflamed syn-
ovium and (b) the strong association of specific HLA (human
leukocyte antigen) class II alleles with disease risk for specific
JRA subtypes [1]. These two observations have been the foun-
dation of the widely accepted theory that JRA pathogenesis is
linked to disordered regulation of T-cell function. According to
this hypothesis, the presence of antigen within the synovium is
the initiating factor leading to the 'homing' of antigen-specific
T cells to the site of antigen deposition (that is, the synovial tis-
sue and fluid).
However, T cell-based hypotheses do not easily account for
the well-documented inflammatory aspects of JRA, which
include complement activation [2], immune complex accumu-
lation [3,4], monocyte secretion of tumour necrosis factor-α
(TNF-α) and interleukin (IL)-1β [5], and the predominance of
neutrophils in the synovial fluid [6]. These findings point
toward an important role of innate immune cells, particularly
neutrophils, in this disease. Hence, we have proposed that the
pathogenesis of JRA involves complex interactions between
innate and adaptive immune systems [7].
Neutrophils are known to contribute to rheumatoid arthritis
pathogenesis by the release of oxygen radicals and tissue-
degrading enzymes, which can lead to the degradation of the
articular cartilage [8]. The potential involvement of neutrophils
in JRA pathogenesis has not been well characterised, despite
the fact that neutrophils are the most abundant cells within
JRA synovial fluids [6]. However, new data suggest that neu-
trophils may indeed play an important role in JRA and that neu-
trophil activation products may serve as biomarkers of disease
activity [9]. We used genome-scale expression profiling to
examine neutrophil function in children with polyarticular onset
JRA, specifically testing the hypothesis that chronic, peripheral
neutrophil activation is a characteristic feature of the disease.
Materials and methods
Study subjects
We studied 25 children newly diagnosed with rheumatoid fac-
tor-negative, polyarticular JRA. Diagnosis was based on
accepted and validated criteria endorsed by the American
College of Rheumatology (ACR) [10]. Children were excluded
if they had been treated with corticosteroids or methotrexate,
or if they had received therapeutic doses of nonsteroidal anti-
inflammatory drugs for more than 3 weeks prior to study.
Patients with active disease ranged in age from 4 to 15 years
and presented with proliferative synovitis of multiple joints. All
had joint activity scores of at least 15 using a standard scoring
system [11] based on that used in pediatric rheumatology clin-
ical trials [12]. Children followed longitudinally were desig-
nated as having a 'partial response' to therapy if they met
American College of Rheumatology-30 improvement criteria
from their baseline state. Children were designated to have
inactive disease if there was no objective synovitis on exam,
morning stiffness for not more than 20 minutes/day, and a nor-
mal erythrocyte sedimentation rate. In addition, we studied 14
of these children on more than one occasion to observe
changes in gene expression pattern in response to therapy.
S100A8/A9 protein levels, a marker of neutrophil-endothelial
cell interactions (see below), were studied in 24 children, 20
of whom were studied on more than one occasion to observe
responses to therapy.
Healthy control subjects (n = 10) were young adults (age 18
to 30) with no history of rheumatic or chronic inflammatory dis-
ease. Previously published work from our group [13] has dem-
onstrated that such subjects are appropriate controls for gene
expression studies in children with polyarticular JRA because
gene expression profiles of peripheral blood buffy coats of
children with polyarticular JRA revert toward patterns indistin-
guishable from such healthy controls after treatment.
NM_001045 SLC6A4 Solute carrier family 6 (neurotransmitter transporter, 
serotonin), member 4
22.8 44.5 2.0
NM_003105 SORL1 Sortilin-related receptor, L(DLR class) A repeats-
containing
31.9 89.7 2.8
NM_003153 STAT6 Signal transducer and activator of transcription 6, 
interleukin-4 induced
1.6 7.9 5.0
NM_003263 TLR1 Toll-like receptor 1 10.4 28.6 2.8
NM_003841 TNFRSF10C Tumour necrosis factor receptor superfamily, member 
10c, decoy without an intracellular domain
8.9 39.6 4.5
NM_006573 TNFSF13B Tumour necrosis factor (ligand) superfamily, member 13b 9.2 22.4 2.4
NM_003329 TXN Thioredoxin 9.0 24.8 2.8
Avg. control, average (normalised) intensity in controls; Avg. patients = average (normalised) intensity in patients; Ratio P/C, fold difference 
between patients and controls.
Table 1 (Continued)
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Sample preparation and RNA purification
After the execution of the informed consent process as
approved by the Oklahoma University Health Sciences Center
(OUHSC) Institutional Review Board, whole blood (20 cc)
was drawn into sterile sodium citrate tubes containing a cell
density gradient (cat no. 362761; BD Biosciences, San Jose,
CA, USA) and carried immediately to the Pediatric Rheumatol-
ogy Research laboratories on the OUHSC campus. Granulo-
cytes were immediately separated from mononuclear cells by
density gradient centrifugation. Centrifugation was performed
at room temperature, resulting in the red cells and granulo-
cytes' layering in the bottom of the tube. Red cells were
removed from the granulocytes by hypotonic cell lysis as rec-
ommended by the manufacturer, and granulocytes were
placed immediately in Trizol reagent for RNA purification.
Plasma was removed and stored at -80°C until used in
enzyme-linked immunosorbent assays (ELISAs) for S100 pro-
tein levels (see below). Cells prepared in this fashion are more
than 98% CD66b+ by flow cytometry and contain no contam-
inating CD14+ cells. Granulocytes were immediately placed in
Trizol reagent (Invitrogen, Carlsbad, CA, USA), and RNA was
purified exactly as recommended by the manufacturer. RNA
was stored under ethanol at -80°C until used for hybridisation
and labeling.
Gene expression arrays
The arrays used in these experiments were developed at the
Oklahoma Medical Research Foundation Microarray Core
Facility in collaboration with QIAGEN Operon (Alameda, CA,
USA). Microarrays were produced using commercially availa-
ble libraries of 70-nucleotide-long DNA molecules whose
length and sequence specificity were optimised to reduce the
cross-hybridisation problems encountered with cDNA-based
microarrays. The microarrays had 21,329 human genes repre-
sented. The oligonucleotides were derived from the UniGene
and RefSeq databases. For the genes present in this data-
base, information on gene function, chromosomal location,
and reference naming are available. All 11,000 human genes
of known or suspected function were represented on these
arrays. In addition, most undefined open reading frames were
represented (approximately 10,000 additional genes).
Oligonucleotides were spotted onto Corning® UltraGAPS™
amino-silane-coated slides (Acton, MA, USA), rehydrated with
water vapor, snap-dried at 90°C, and then covalently fixed to
the surface of the glass using 300-mJ, 254-nm wavelength UV
radiation. Unbound free amines on the glass surface were
blocked for 15 minutes with moderate agitation in a 143 mM
solution of succinic anhydride dissolved in 1-methyl-2-pyrolid-
inone, 20 mM sodium borate, pH 8.0. Slides were rinsed for 2
minutes in distilled water, immersed for 1 minute in 95% etha-
nol, and dried with a stream of nitrogen gas.
RNA labeling and hybridization
Prior to cDNA synthesis, the RNA was resuspended in diethyl-
pyrocarbonate-treated water. RNA integrity was assessed
using capillary gel electrophoresis (Agilent 2100 BioAnalyzer;
Agilent Technologies, Inc., Palo Alto, CA, USA) to determine
the ratio of 28 s/18 s rRNA in each sample. A threshold of 1.0
was used to define samples of sufficient quality, and only sam-
ples above this limit were used for microarray studies. cDNA
was synthesised using Omniscript reverse transcriptase (Qia-
gen, Valencia, CA, USA) with direct incorporation of cyanine
3-dUTP (deoxy-uridine triphosphate) from 2 µg of RNA.
Labeled cDNA was purified using a Montage 96-well vacuum
system (Millipore Corporation, Billerica, MA). The cDNA was
added to hybridisation buffer containing CoT-1 DNA (0.5 mg/
ml final concentration), yeast tRNA (0.2 mg/ml), and
poly(dA)40–60 (0.4 mg/ml). Hybridisation was performed in an
automated liquid delivery, air-vortexed, hybridisation station for
9 hours at 58°C under an oil-based coverslip (Ventana Medi-
cal Systems, Inc., Tucson, AZ, USA). Microarrays were
washed at a final stringency of 0.1 × SSC (saline-sodium cit-
rate). Microarrays were scanned using a simultaneous dual-
colour, 48-slide scanner (Agilent Technologies, Inc.). Fluores-
cent intensity was quantified using Koadarray™ software
(Koada Technology, Kippen, Sterling, UK).
Array analysis
Data were subject to normalisation and regression steps as
described in detail in our earlier work [13]. Genes differentially
expressed between groups of samples were selected using
associative analysis [13]. Genes selected to be differentially
expressed in any sample combinations were used to classify
patients, including active, partial and inactive, and control sam-
ples using hierarchical clustering. The analysis package is pro-
vided by Spotfire DecisionSite for Functional Genomics 8.1
(Spotfire, Inc., Somerville, MA, USA). Similarity measure was
the Euclidean distance, the clustering method was
Unweighted Pair Group Method with Arithmetic Mean, and
input rank was the ordering function.
Forty-two of the most highly expressed up- or downregulated
genes in patients with JRA were used in pathway modeling
using PathwayAssist Software (Ariadne Genomics Inc., Rock-
ville, MD, USA). Relationships of protein nodes with H2O2 and
calcium were preserved intentionally to reveal the overall net-
working of calcium influx and peroxide metabolism, which are
highly specific to the function of neutrophils.
Hypervariable (HV) genes are a group of genes whose expres-
sions exhibit higher variation than biological fluctuation base-
line, as we have described previously [14]. After the HV genes
were selected, they were clustered using an F-means cluster-
ing method to determine each gene's cluster association and
its connectivity with other genes. Genes were sorted based on
their cluster association and connectivity in the control group,
with the gene of the highest connectivity of the first clusterAvailable online http://arthritis-research.com/content/8/5/R154
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Table 2
Genes under-expressed in patients with JRA
GenBank accession no. Symbol Description Avg. control Avg. patients Ratio C/P
NM_001145 ANG Angiogenin, ribonuclease, RNase A family, 5 18.8 6.1 3.1
NM_000041 APOE Apolipoprotein E 16.9 7.2 2.3
NM_002983 CCL3 chemokine (C-C motif) ligand 3 166.7 7.4 22.4
D90145 CCL3L1 chemokine (C-C motif) ligand 3-like 1 197.7 21.4 9.2
NM_002984 CCL4 chemokine (C-C motif) ligand 4 221.7 22.2 10.0
NM_002985 CCL5 chemokine (C-C motif) ligand 5 38.5 8.3 4.7
NM_001781 CD69 CD69 antigen (p60, early T-cell activation antigen) 23.5 4.5 5.2
NM_004233 CD83 CD83 antigen (activated B lymphocytes, 
immunoglobulin superfamily)
24.3 0.1 365.9
NM_031226 CYP19A1 cytochrome P450, family 19, subfamily A, 
polypeptide 1
25.8 9.2 2.8
NM_004408 DNM1 Dynamin 1 13.6 4.1 3.3
NM_004418 DUSP2 Dual specificity phosphatase 2 54.1 7.8 6.9
NM_000114 EDN3 Endothelin 3 36.7 11.8 3.1
NM_001961 EEF2 Eukaryotic translation elongation factor 2 114.1 29.1 3.9
NM_005252 FOS V-fos FBJ murine osteosarcoma viral oncogene 
homolog
483.5 100.4 4.8
NM_006732 FOSB FBJ murine osteosarcoma viral oncogene homolog B 89.6 11.7 7.7
NM_015675 GADD45B Growth arrest and DNA-damage-inducible, beta 87.5 19.3 4.5
NM_012483 GNLY Granulysin 47.5 2.5 19.2
NM_006144 GZMA Granzyme A (granzyme 1, cytotoxic T-lymphocyte-
associated serine esterase 3)
15.3 4.5 3.4
NM_019111 HLA-DRA Major histocompatibility complex, class II, DR alpha 226.5 33.9 6.7
NM_006895 HNMT Histamine N-methyltransferase 13.4 4.4 3.1
NM_031157 HNRPA1 Heterogeneous nuclear ribonucleoprotein A1 31.8 8.8 3.6
NM_014365 HSPB8 heat shock 22-kDa protein 8 23.8 7.0 3.4
NM_000576 IL1B Interleukin 1, beta 169.0 22.4 7.5
AK055991 LAMR1 Laminin receptor 1 (67 kDa, ribosomal protein SA) 35.3 14.2 2.5
NM_002305 LGALS1 Lectin, galactoside-binding, soluble, 1 (galectin 1) 15.5 4.3 3.6
X60188 MAPK3 Mitogen-activated protein kinase 3 228.5 81.3 2.8
NM_020529 NFKBIA Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha
705.4 56.0 12.6
NM_002135 NR4A1 Nuclear receptor subfamily 4, group A, member 1 46.0 15.4 3.0
NM_006186 NR4A2 Nuclear receptor subfamily 4, group A, member 2 35.7 9.5 3.8
U12767 NR4A3 Nuclear receptor subfamily 4, group A, member 3 18.3 4.4 4.2
BC011589 OSM Oncostatin M 19.8 5.3 3.8
NM_002659 PLAUR Plasminogen activator, urokinase receptor 23.8 4.8 4.9
NM_000311 PRNP Prion protein (p27-30) 15.0 5.1 3.0
NM_000963 PTGS2 Prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase)
174.9 30.4 5.8
NM_002823 PTMA Prothymosin, alpha (gene sequence 28) 169.0 56.0 3.0
NM_000994 RPL32 Ribosomal protein L32 174.4 58.6 3.0
NM_002966 S100A10 S100 calcium binding protein A10 (annexin II ligand, 
calpactin I, light polypeptide [p11])
33.9 9.2 3.7
NM_003745 SOCS1 suppressor of cytokine signaling 1, SSI-1 23.1 8.2 2.8Arthritis Research & Therapy    Vol 8 No 5    Jarvis et al.
Page 6 of 14
(page number not for citation purposes)
ranked on the top. To reveal the intrinsic dynamic relationship
between each gene in a sample group, a matrix of correlation
coefficiency was displayed in a colour mosaic.
Polymerase chain reaction validation of array data
Six down randomly selected genes in the patients with polyar-
ticular JRA and controls were selected for reverse transcrip-
tion-polymerase chain reaction (PCR) confirmation.
Reverse transcription
Three controls and three patients were used for PCR valida-
tion. First-strand cDNA was generated from 1.2 µg of total
RNA per sample with 0.1 ng of the exogenous control Arabi-
dopsis  RUBISCO mRNA (RCA) spiked in (Stratagene, La
Jolla, CA, USA) according to the OmniScript Reverse Tran-
scriptase manual, except for the use of 500 ng anchored oligo
dT primer (dT20VN). cDNA was purified with the Montage
PCR Cleanup kit (Millipore Corporation) according to manu-
facturer's instructions. cDNA was diluted 1:20 in water and
stored at -20°C.
Quantitative PCR
Gene-specific primers for the human genes CD74, V-FOS,
NFKBIA, PTGS2, SCYA3L1, SCYA4, and the Arabidopsis
gene RCA were designed with a 60°C melting temperature
and a length of 19 to 25 bp for PCR products with a length of
90 to 130 bp, using ABI Primer Express 1.5 software (Applied
Biosystems, Foster City, CA, USA). PCR was run with 2 µl
cDNA template in 15 µl reactions in triplicate on an ABI SDS
7700 using the ABI SYBR Green I Master Mix and gene-spe-
cific primers at a concentration of 1 µM each. The temperature
profile consisted of an initial 95°C step for 10 minutes (for Taq
activation), followed by 40 cycles of 95°C for 15 seconds,
60°C for 1 minute, and then a final melting curve analysis with
a ramp from 60°C to 95°C for 20 minutes. Gene-specific
amplification was confirmed by a single peak in the ABI
Dissociation Curve software. No template controls were run
for each primer pair and no RT controls were run for each sam-
ple to detect nonspecific amplification or primer dimers. Aver-
age threshold cycle (Ct) values for RCA (run in parallel
reactions to the gene of interest) were used to normalise aver-
age Ct values of the gene of interest. These values were used
to calculate the average group (normal versus patient), and the
relative ∆Ct was used to calculate fold change between the
two groups.
ELISA for S100 A8/A9
Costar High Binding 96-well plates (Corning Life Sciences,
Acton, MA, USA) were coated with 100 µl/well of S100A8/
A9-specific monoclonal antibody 5.5 (kindly provided by Dr.
Nancy Hogg, Cancer Research UK, London, UK) diluted to a
concentration of 1 µg/ml in 0.1 M carbonate buffer (pH 9.6)
and left overnight at 4°C. After incubation, the plates were
washed with phosphate-buffered saline (PBS)/0.1% Tween-
20 and blocked with PBS/0.1% Tween-20/2% bovine serum
albumin (BSA) (100 µl/well) for 30 minutes at room tempera-
ture. The samples (plasma from children with polyarticular JRA
and healthy controls) and standards (100 µl) were added and
incubated for 40 minutes at room temperature. After three
washes with PBS/0.1% Tween-20, the plates were incubated
with 100 µl/well of S100A9 polyclonal antibodydiluted
1:10,000 in PBS/0.1% Tween-20/2% BSA for 40 minutes at
room temperature. After incubation, the plates were washed
three times and incubated with 100 µl/well of peroxidase-con-
jugated donkey anti-rabbit immunoglobulin G (IgG) at a dilu-
tion of 1:7,500 in PBS/0.1% Tween-20/2% BSA for 40
minutes at room temperature. After three washes, the pres-
ence of IgG was detected with 100 µl of a peroxidase sub-
strate solution (3,3',5,5'-tetramethylbenzidine; RDI Division of
Fitzgerald Industries Intl, Concord, MA, USA, formerly
Research Diagnostics Inc.) according to the manufacturer's
instructions; the reaction was stopped by adding 100 µl of
0.36 mM H2SO4, and the optical density was read at 500 nm.
Results from patient samples were compared against stand-
ards of known S100A8/A9 concentration. The detection limit
for this assay is 1 ng/ml A8/A9 dimer. The antibodies used in
this assay have been tested against murine S100A8 and
S100A9, bovine S100A and S100B, and human S100A12
and found to be specific.
Results were tabulated in a commercially available statistics
and graphics software program (GraphPad Prism; GraphPad
Software, Inc., San Diego, CA, USA), and comparisons of chil-
dren with active and inactive polyarticular JRA and controls
were accomplished using a two-tailed independent t test.
Results ≤ 0.05 were considered statistically significant.
Immunofluorescence staining
Neutrophils were placed on glass coverslips, incubated with 1
µg fluorescein isothiocyanate (FITC)-conjugated anti-mye-
loperoxidase (MPO) at 4°C for 30 minutes, and then washed
NM_032298 SYT3 synaptotagmin III, DKFZp761O132 30.2 11.4 2.7
NM_003246 THBS1 Thrombospondin 1 33.7 11.1 3.0
NM_006290 TNFAIP3 Tumour necrosis factor, alpha-induced protein 3 112.1 24.9 4.5
NM_003407 ZFP36 Zinc finger protein 36, C3H type, homolog (mouse) 177.8 51.5 3.5
Avg. control, average (normalised) intensity in controls; Avg. patients, average (normalised) intensity in patients; Ratio C/P, fold difference between 
controls and patients.
Table 2 (Continued)
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again with Hanks' balanced salt solution at room temperature.
Cells were observed using an axiovert fluorescence micro-
scope (Carl Zeiss, Inc., Thornwood, NY, USA) with mercury
illumination interfaced to a computer using Scion image
processing software (Scion Corporation, Frederick, MD,
USA). A narrow band-pass discriminating filter set (Omega
Optical, Inc., Brattleboro, VT, USA) was used with excitation at
485/22 nm and emission at 530/30 nm for FITC. A long-pass
dichroic mirror of 510 nm was used. The fluorescence images
were collected with an intensified charge-coupled device
camera (Princeton Instruments Inc., Trenton, NJ, USA).
Detection of NAD(P)H oscillations
NAD(P)H autofluorescence oscillations were detected as
described [15,16]. An iris diaphragm was adjusted to exclude
light from neighboring cells. A cooled photomultiplier tube
held in a model D104 detection system (Photon Technology
International, Inc., Birmingham, NJ, USA) attached to a micro-
scope (Carl Zeiss, Inc.) was used.
Results
Microarray analysis of peripheral blood JRA neutrophils
A total of 712 genes were shown to have differential levels of
expression between the patients with polyarticular JRA and
the control subjects. For simplicity, the 84 genes showing the
highest levels of differential expression expression are shown
in Table 1 (genes over-expressed in polyarticular JRA neu-
trophils) and Table 2 (genes under-expressed in polyarticular
JRA neutrophils). The full data sets are available online [17].
Genes over-expressed in patients with polyarticular JRA
included principally mediators and regulators of oxidative
response, neutrophil activation, and inflammation control
(Table 1) (Figure 1), suggesting that peripheral neutrophils are
active in patients with polyarticular JRA and contribute to the
systemic inflammatory nature of this disorder. These results
provide a catalog of neutrophil-mediated aspects of disease
pathology, with both well-characterised and putative patho-
genic pathways identified, suggesting that inhibition of neu-
trophil activity may provide a useful means of limiting key
aspects of the pathology of polyarticular JRA. Genes down-
regulated in JRA neutrophils relative to healthy controls (Table
2) included the immune and inflammatory mediators CCL3,
CCL4,  CCL5,  IL-1B,  COX-2,  MHC-II DR-α,  granzyme A,
galectin 1, V-Fos, and inhibitor of nuclear factor-κB-α.
Validity of the array data was then tested using quantitative
real-time PCR on the six randomly selected genes (Figure 2).
In each case, real-time PCR data corroborated the array find-
ings, as shown in Table 3.
To determine the functional relationship among these genes,
computer modeling based on the differentially expressed
genes was used. These studies indicated links to both innate
and adaptive immunity (Figure 1), with clusters of both inter-
leukin (IL)-8- and interferon-γ (IFN-γ)-regulated genes differen-
tially expressed in children with polyarticular JRA and control
subjects. Furthermore, multiple genes in the computer model
were linked to both calcium influx (Figure 1, top left) and super-
oxide ion production (green circles, 'H2O2'). These findings
were of considerable interest given that IL-8 and IFN-γ inde-
pendently regulate oscillations of key metabolites in neu-
trophils, which in turn regulate both calcium ion influx and
superoxide ion release [18]. This model was tested directly
using single-cell autofluorescence, as described below.
Genomic evidence for persistence of disease activity in 
JRA neutrophils
Hierarchical clustering of genes that were differentially
expressed in patients with polyarticular JRA was used to group
individuals who have similar expression profiles in their periph-
eral blood neutrophils. Patients with polyarticular JRA and con-
trols formed distinct clusters, confirming the validity of the
differential gene expression analysis on a global scale.
Figure 3 shows a hierarchal cluster analysis of neutrophil
mRNA expression in children with polyarticular JRA and a
panel of eight healthy control subjects. Children were grouped
according to disease activity as described in Materials and
methods. Of note is that healthy control subjects cluster
together at the left side of the graph. Children with polyarticu-
lar JRA, however, scatter across the graph regardless of dis-
ease activity. That is, children with polyarticular JRA showed
persistent abnormalities in neutrophil gene expression when
their disease was well controlled. This finding was similarly
demonstrated using the connectivity analysis procedure (Fig-
ure 4) described in Materials and methods and in our previ-
ously published work [13,14]. The contingency analysis for
these selected genes demonstrated disruption of normal gene
relationships in neutrophils of children with polyarticular JRA
when those relationships were compared with healthy con-
trols. These findings strongly suggest that neutrophils are
chronically dysregulated in polyarticular JRA and that therapy
only minimally ameliorates the disordered pattern.
To further support a role for chronic neutrophil activation in
polyarticular JRA, we examined S100A8/A9 and S100A12
plasma levels. Both S100A8/A9 and S100A12 (data not
shown) were identified as over-expressed in patients with pol-
yarticular JRA (relative to controls; Figure 1) in array experi-
ments and confirmed on real-time PCR analysis. These
proteins are highly expressed in neutrophils and monocytes
(up to 40% of cytosolic proteins), are released upon cell acti-
vation, and contribute to the migration of neutrophils to inflam-
matory sites [19,20]. As predicted from the array data, S100
proteins were markedly elevated in children with polyarticular
JRA (662 ± 40 ng/ml) compared with controls (40 ± 9 ng/ml;
p > 0.001; Figure 5a). Children with inactive disease (198 ±
60 ng/ml) had lower levels of S100 proteins compared with
children with active disease (p = 0.007; Figure 5b), but levels
were still significantly higher (p = 0.047) than those seen inArthritis Research & Therapy    Vol 8 No 5    Jarvis et al.
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healthy controls (Figure 5c). These findings suggest that
neutrophils in children with polyarticular JRA remain in an acti-
vated state during disease quiescence.
The computer model generated through analysis of differen-
tially expressed genes (Figure 1) suggested pathologically rel-
evant links between IL-8- and IFN-γ-regulated genes in
polyarticular JRA neutrophils and that gene expression was
functionally linked to calcium influx and superoxide ion
production. IL-8 and IFN-γ independently regulate oscillatory
phenomena in neutrophils, with IFN-γ regulating amplitude and
IL-8 oscillatory frequency. We proceeded to test that model by
monitoring the autofluoresence of NAD(P)H in living neu-
trophils, which reflects various stages and mechanisms of neu-
trophil activation [21]. Metabolic oscillations of neutrophils
from six children with polyarticular JRA and five healthy control
subjects were monitored. Figure 6 provides representative
tracings of NAD(P)H oscillations in resting and stimulated
cells from patients. Because metabolic frequencies and ampli-
tudes have been linked with the hexose monophosphate shunt
activity and the peroxidase cycle, respectively, we assessed
MPO surface expression on living neutrophils. In contrast to
controls that show no MPO surface expression, all patients
with polyarticular JRA demonstrated a subpopulation of neu-
trophils (10% to 23% of the cells) that expressed surface-
associated myeloperoxidase. Neutrophils staining MPO-nega-
tive from patients responded to lipopolysaccharide (LPS) stim-
ulation by increasing the frequency of NAD(P)H oscillations,
reducing the period from 20 to 10 seconds, as previously
described in activated neutrophils [18]. This behaviour is iden-
tical to that observed for control neutrophils. However, MPO-
positive neutrophils from patients with polyarticular JRA
Figure 1
Computer model of differentially expressed genes in juvenile rheumatoid arthritis and control neutrophils developed from PathwayAssist software as  described in Materials and methods Computer model of differentially expressed genes in juvenile rheumatoid arthritis and control neutrophils developed from PathwayAssist software as 
described in Materials and methods. Note upregulation of S100 proteins in patients (top left). Also note clusters of genes independently or interde-
pendently regulated by interleukin-8 or interferon-γ (blue circles, bottom left and right). Finally, computer modeling showed significant associations 
between differentially expressed genes and the regulation of fundamental metabolic processes such as H2O2 production (multiple green circles) and 
calcium influx (top left).Available online http://arthritis-research.com/content/8/5/R154
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(including two with inactive disease) demonstrated increases
in both frequency and amplitude in NAD(P)H oscillation after
LPS stimulation. In contrast, activated control cells show no
changes in metabolic amplitude. This novel finding suggests a
fundamental breakdown in the regulation of neutrophil metab-
olism, as will be discussed below. We are now preparing to
determine whether the number of aberrantly functioning,
MPO-positive cells changes with disease severity or during
the course of therapy.
Discussion
Polyarticular and pauciarticular JRA have long been assumed
to be T cell-driven autoimmune diseases [22]. However,
involvement of the innate immune system, at least in the pol-
yarticular form of JRA, has long been recognised and is dem-
onstrated by abundant experimental evidence [2-5].
Furthermore, the most successful new therapies for the treat-
ment of polyarticular JRA have been those directed at
cytokines released during the innate immune response (that is,
TNF-α and IL-1) [23]. Despite this tantalising evidence that
innate immunity plays a critical role in the pathogenesis of pol-
yarticular JRA, this aspect of the immune response has been
largely overlooked in investigations into basic disease
mechanisms.
We demonstrate that neutrophils from children with polyartic-
ular JRA show persistent abnormalities even after the disease
has responded to therapy. Furthermore, this observation is
supported using multiple measures of neutrophil structure and
function. Gene microarrays, plasma S100 protein levels, and
single-cell auto fluorescence support the hypothesis that there
is a fundamental activation abnormality in neutrophils of chil-
dren with polyarticular JRA. These studies also demonstrate
that multiple methods of analysis applied to gene expression
studies can uncover important clues into disease
pathogenesis.
We used computer modeling to attempt to unravel the patho-
genic clues behind our array data, as we did in a smaller study
[13]. Three interesting patterns emerged from that analysis
(Figure 1): (a) high levels of mRNA for proteins that regulate
neutrophil-endothelial cell interactions (that is, S100A8/A9
and S100A12), (b) large numbers of genes controlling or con-
trolled by superoxide ion production, and (c) genes independ-
ently and interdependently regulated by IFN-γ and IL-8. The
significance of these findings will be discussed in the following
paragraphs.
S100 proteins (also known as calgranulins or myeloid-related
proteins) are released from neutrophils during interactions
with activated endothelium [24]. Other authors have previ-
ously demonstrated that these proteins are elevated in chil-
dren with both poly- and pauciarticular JRA and have
suggested that S100 protein levels may be useful biomarkers,
as their levels remain elevated even after other markers of dis-
ease activity (for example, erythrocyte sedimentation rate or
plasma C-reactive protein) return to normal [25]. Although the
clinical utility of measuring S100 protein levels has yet to be
demonstrated, we believe that they provide important insights
into JRA disease pathogenesis. We have previously proposed
that the endothelium represents a critical, and under-investi-
gated, factor in JRA pathogenesis [6]. In vitro models,
furthermore, support the notion that there are likely to be com-
plex interactions among circulating immune aggregates, leuko-
cytes, and endothelium in polyarticular JRA [26,27],
interactions which (in and of themselves) may lead to low-level
T-cell activation without the addition of TCR-CD3-transduced
signaling [28]. The presence of elevated levels of S100 pro-
teins in polyarticular JRA suggests dysregulation of neutrophil-
endothelial cell interactions, but whether the primary abnor-
mality lies in the neutrophils or endothelium cannot be
deduced by examining S100 protein levels alone. It is also
important to note that S100A8/A9 activates T lymphocytes
[29] and could therefore participate in T-cell activation com-
monly thought to be involved in JRA pathogenesis.
The finding of clusters of IFN-γ- and IL-8-regulated genes dif-
ferentially expressed in polyarticular JRA neutrophils was of
considerable interest, as IFN-γ and IL-8 independently regu-
late neutrophil oscillatory activities. Oscillatory phenomena are
Figure 2
Validation of microarray data with quantitative real-time polymerase  chain reaction (QRT-PCR) showing a representative experiment  (repeated one additional time) Validation of microarray data with quantitative real-time polymerase 
chain reaction (QRT-PCR) showing a representative experiment 
(repeated one additional time). Three controls and three patients were 
selected for QRT-PCR to validate microarray results. QRT-PCR was 
carried out for individual samples, and then the average threshold cycle 
(Ct) of the patients and the average Ct of the healthy controls were 
used to calculate relative expression, expressed as fold change. The 
fold changes of both microarray (open bars) and QRT-PCR (solid bars) 
are shown. For all six genes selected, relative expression was higher in 
healthy controls relative to patients as shown by microarrays and QRT-
PCR, thus confirming the microarray results.Arthritis Research & Therapy    Vol 8 No 5    Jarvis et al.
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seen on both a macroscopic and microscopic level in biologi-
cal systems. On the macroscopic level, the most obvious
examples would be heartbeat and respiration. However, levels
of key metabolites, including superoxide ion and NAD(P)H,
also have been shown to oscillate in neutrophils, and these
oscillations are causally linked to downstream neutrophil effec-
tor functions [30]. Known inflammatory mediators, including
TNF-α, IFN-γ, IL-2, and IL-8, regulate these oscillatory phe-
nomena. However, amplitude enhancement and frequency
enhancement are controlled by separate, independent, and
well-insulated metabolic pathways. IL-8 regulates changes in
oscillation frequency, and IFN-γ regulates changes in oscilla-
tion amplitude [31]. Thus, the finding that a subpopulation of
polyarticular JRA neutrophils exhibit loss of insulation separat-
ing the mechanisms that normally regulate amplitude and fre-
quency enhancement is both novel and intriguing. It is
important to point out that the defect in metabolic dynamics is
contingent upon activation of the hexose monophosphate
shunt pathway. That is, there is no defect in JRA until the shunt
is activated by LPS or fMLP (N-formyl-L-methionyl-L-leucyl-L-
phenylalanine) (data not shown). However, when the shunt is
activated in polyarticular JRA neutrophils, both metabolic path-
ways are triggered, which leads to an exaggerated cell
response. This process, like S100 protein levels, is likely tied
to enhanced secretory activity, in that myeloperoxidase, like
S100 proteins, is normally stored in intracellular granules and
not released in control cells, although surface expression is
seen for some polyarticular JRA neturophils. Precisely how this
occurs and how the defect relates (or is related) to the altered
expression of IL-8- and IFN-γ-regulated genes are now the
subject of investigation in our laboratories.
There are obviously some unanswered questions that emerge
from this study. The first is whether the neutrophil defect is
primary or secondary and how it relates (if at all) to adaptive
immune processes believed to be operative in polyarticular
Figure 3
Hierarchical cluster analysis of microarray data in juvenile rheumatoid arthritis (JRA) neutrophils Hierarchical cluster analysis of microarray data in juvenile rheumatoid arthritis (JRA) neutrophils. Data show clustering of control subjects to the left 
of the grid based on patterns of gene expression. Data of children with JRA are scattered on the right side of the grid regardless of disease status. 
That is, data of children with active disease (A) cluster together with those of children with partially responsive disease (P) and inactive disease (fully 
responsive disease) (R).
Table 3
Summary of real-time polymerase chain reaction data
Fold change (control > patient)




CD74 5.9 1.7 Yes
PTGS2 7.6 2.2 Yes
V-FOS 10.6 2.3 Yes
NFKB1A 19.1 7.2 Yes
SCYA3L1 10.8 23.7 Yes
SCYA4 12 27.3 YesAvailable online http://arthritis-research.com/content/8/5/R154
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JRA. Previous studies reported from our group [13] support
the hypothesis that the defect may be primary. In earlier stud-
ies of JRA using whole blood buffy coats, we demonstrated
both by discriminant function analysis and connectivity analy-
ses identical to those shown in Figure 4 that JRA gene expres-
sion patterns return to normal after response to pharmacologic
therapy, regardless of the therapy used. In this larger study
using a more robust gene array, we demonstrate that abnormal
patterns of neutrophil gene expression persist even when the
disease is inactive.
Another question that arises is that of specificity. It is reason-
able to ask, for example, whether the same or similar abnormal-
ities of gene expression and neutrophil activation may not be
part of other JRA subtypes or any other chronic inflammatory
state. The elevation of S100A8/A9 complexes in the serum
are clearly not specific to polyarticular JRA, as such elevations
Figure 4
Contingency analyses of neutrophils from children with juvenile rheumatoid arthritis (JRA) and controls Contingency analyses of neutrophils from children with juvenile rheumatoid arthritis (JRA) and controls. Control samples are represented on the top 
left panel. Families of genes whose expression levels correlated positively (red) or negatively (green) with one another are displayed on the grid. 
These same relationships are distorted in neutrophils of children with active polyarticular JRA (bottom right panel) and are only partially restored after 
full response to therapy (top right panel).Arthritis Research & Therapy    Vol 8 No 5    Jarvis et al.
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have been described in other JRA subtypes [32,33] and other
chronic inflammatory diseases [34,35]. However, even if these
findings are not specific for polyarticular JRA, they point to
important, previously unrecognised contributions of neu-
trophils in JRA pathogenesis and the need to examine in much
more detail than has been previously the case the role of
innate immunity in JRA pathogenesis. Despite their limits, our
data suggest that there may be pathogenic similarities
between polyarticular JRA and chronic autoinflammatory
states such as NOMID (neonatal onset multisystem inflamma-
tory disease) [36] and related disorders of neutrophil activa-
tion [37].
We have demonstrated through multiple lines of evidence that
polyarticular JRA is associated with chronic, dysregulated neu-
trophil activation. Further investigations into the role of
neutrophils in the JRA subset are likely to yield novel and unex-
pected insights into disease pathogenesis.
Conclusion
We provide evidence that the neutrophils in polyarticular JRA
are in a chronic, activated state. These findings suggest that
neutrophils play a critical role in disease pathogenesis.
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